ArticleCommunications medicine2025
A peptide-based medical device for the selective removal of inflammatory factors from the blood of people with sepsis.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cooperative Oligomeric Peptide Combinations Enhance the Predicted Therapeutic Profile of SET-M33.Antibiotics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a complex life-threatening clinical condition associated with significant morbidity and mortality. It is usually triggered by an infection, the cellular response to which progresses, involving the innate immune system and leading to a cytokine storm that can provoke death.
methodsThe device is based on the peptide SET-M33, an antimicrobial molecule with strong antibacterial activity. The peptide was conjugated with a biocompatible agarose matrix via a covalent sulfonic bridge, then encapsulated in a device to insert in a circulation system. Here we describe a medical device that selectively and simultaneously remove the major triggers of the onset and progression of sepsis from the blood of sepsis patients. These include live bacteria and their components, such as lipopolysaccharides (LPS) and lipoteichoic acids (LTA), as well as C reactive protein (CRP).
resultsIn a human serum assay, the device removes 85% of LPS, >80% of LTA, >99% of live Gram-positive and Gram-negative bacteria in serum, and >94% of CRP. In ex vivo animal model in which murine blood spiked with known amounts of LPS, the device removes >80% of the endotoxin. After circulation in the device, the serum shows no significant change in protein content, this confirms that the device does not change the molecular profile of the blood.
conclusionsThe instrument here described is a prototype with strong potential for clinical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.